1. Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy.
- Author
-
Jilg, Nikolaus, Garcia-Broncano, Pilar, Peluso, Michael, Segal, Florencia P, Bosch, Ronald J, Roberts-Toler, Carla, Chen, Samantha M Y, Dam, Cornelius N Van, Keefer, Michael C, Kuritzkes, Daniel R, Landay, Alan L, Deeks, Steven, Yu, Xu G, Sax, Paul E, Li, Jonathan Z, Team, AIDS Clinical Trials Group A5308 Study, Van Dam, Cornelius N, and AIDS Clinical Trials Group A5308 Study Team
- Subjects
HIV ,ANTIRETROVIRAL agents ,VIRAL load ,AIDS ,PROTEASE inhibitors ,HIV infections ,RESEARCH ,RESEARCH methodology ,HIV protease inhibitors ,IMMUNOLOGY technique ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,VIREMIA ,RESEARCH funding ,T cells ,LONGITUDINAL method - Abstract
AIDS Clinical Trials Group study A5308 found reduced T-cell activation and exhaustion in human immunodeficiency virus (HIV) controllers start antiretroviral therapy (ART). We further assessed HIV-specific T-cell responses and post-ART viral loads. Before ART, the 31% of participants with persistently undetectable viremia had more robust HIV-specific T-cell responses. During ART, significant decreases were observed in a broad range of T-cell responses. Eight controllers in A5308 and the Study of the Consequences of the Protease Inhibitor Era (SCOPE) cohort showed no viremia above the level of quantification in the first 12 weeks after ART discontinuation. ART significantly reduced HIV-specific T-cell responses in HIV controllers but did not adversely affect controller status after ART discontinuation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF